Pre-eclampsia is a dangerous pregnancy complication characterized by high blood pressure and organ damage — particularly to the kidneys and liver — that can progress to seizures and is life-threatening for mother and baby. It affects about 5% of pregnancies and is a leading cause of preterm birth.
What's actually going on in research
Low-dose aspirin started in the first trimester significantly reduces pre-eclampsia risk in high-risk women, and trials are refining who benefits most and testing combined aspirin-heparin prophylaxis. Fetal growth restriction monitoring and biomarkers including sFlt-1/PlGF ratios are being validated to predict pre-eclampsia weeks before clinical onset. New drugs targeting the angiogenic imbalance (sFlt-1 excess) that causes pre-eclampsia are in early trials.
Aspirin prophylaxis refinement
Low-dose aspirin reduces pre-eclampsia risk by 10–20% in high-risk pregnancies; trials are testing higher doses, timing of initiation, and combined approaches with heparin.
Biomarker-guided prediction
sFlt-1 and PlGF blood tests predict pre-eclampsia up to 4 weeks before diagnosis. Trials are testing whether biomarker-guided monitoring and intervention reduce maternal and neonatal complications.
Anti-angiogenic therapy
Apheresis to remove excess sFlt-1 and drugs that block its production are in early trials to extend pregnancy safely in pre-eclampsia cases developing far before term.
What to know before you search
Eligibility requires either high-risk status (prior pre-eclampsia, chronic hypertension, kidney disease) for prevention trials, or confirmed pre-eclampsia diagnosis for treatment trials.
What types of trials are currently open
- Prevention trials — Testing aspirin, heparin, calcium, and other agents to prevent pre-eclampsia in high-risk pregnancies.
- Biomarker trials — Validating blood and urine tests for early pre-eclampsia prediction and risk stratification.
- Treatment trials — Evaluating antihypertensive drugs, magnesium sulfate, and corticosteroids to manage established pre-eclampsia.
- Intervention trials — Testing therapeutic apheresis and experimental drugs for sFlt-1 reduction in severe early pre-eclampsia.
- Long-term outcomes studies — Tracking maternal cardiovascular and renal health after pre-eclampsia.
Recently added Pre-eclampsia trials
Vitamin D3 Supplementation Regimens and Preeclampsia Risk
This study is a randomized controlled trial with two parallel groups connected at Al-Thawra Modern General Hospital in Sana'a, Yemen. It aims to compara the effect of two different vitamin D3 supplementation regimens during pregnancy on the risk of pre-eclampsia among women with confirmed vitamin D deficiency. Pregnant women attending antenatal care and diagnosed with vitamin D deficiency will be screened for eligibility. Eligible participants will be randomly assigned to one of two intervention groups:one group receiving vitamin D3 50,000 IU every two weeks and the other group receiving vitamin D3 5,000 IU weekly,in addition to standard antenatal care. The study will include singleton pregnancies between 8\_18 weeks of gestation with serum 25-hydroxyvitamin D level below 25 ng /mL . Women with chronic conditions that may affect pregnancy outcomes or vitamin D metabolism will be excluded. Participants will be followed throughout pregnancy to assess the development of pre-eclampsia and other maternal and fetal outcomes.
Test a blood pressure monitor designed for pregnant women
The aim of the study is to assess the accuracy of the automatic oscillometric BP measuring device at the brachial level, the WITHINGS BPM Pro 2, in pregnancy and pre-eclampsia
Find Pre-eclampsia trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.